Sonoma Pharmaceuticals, Inc. (SNOA)
USD 2.25
(-4.66%)
USD 2.25
(-4.66%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -4.7 Million USD | -2.87% |
| 2023 | -4.57 Million USD | 22.37% |
| 2022 | -5.88 Million USD | -70.69% |
| 2021 | -3.44 Million USD | 48.3% |
| 2020 | -6.67 Million USD | 40.74% |
| 2019 | -11.25 Million USD | 20.66% |
| 2018 | -14.18 Million USD | -9.36% |
| 2017 | -12.97 Million USD | -27.8% |
| 2016 | -10.15 Million USD | -52.46% |
| 2015 | -6.65 Million USD | -10.05% |
| 2014 | -6.05 Million USD | -79.34% |
| 2013 | -3.37 Million USD | 47.83% |
| 2012 | -6.46 Million USD | 13.83% |
| 2011 | -7.5 Million USD | 6.37% |
| 2010 | -8.01 Million USD | 53.68% |
| 2009 | -17.3 Million USD | 22.82% |
| 2008 | -22.42 Million USD | -15.09% |
| 2007 | -19.48 Million USD | 6.56% |
| 2006 | -20.85 Million USD | -27.83% |
| 2005 | -16.31 Million USD | -1908.43% |
| 2004 | 902 Thousand USD | 161.44% |
| 2003 | -1.46 Million USD | -898.64% |
| 2002 | -147 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -844 Thousand USD | 30.13% |
| 2024 Q1 | -1.24 Million USD | -8.11% |
| 2024 Q2 | -1.2 Million USD | 2.58% |
| 2024 FY | -4.7 Million USD | -2.87% |
| 2024 Q4 | -1.4 Million USD | -66.94% |
| 2023 Q2 | -731 Thousand USD | 14.5% |
| 2023 Q1 | -855 Thousand USD | 72.06% |
| 2023 Q4 | -1.14 Million USD | 37.46% |
| 2023 FY | -4.57 Million USD | 22.37% |
| 2023 Q3 | -1.83 Million USD | -150.89% |
| 2022 Q2 | -964 Thousand USD | -6.64% |
| 2022 Q4 | -3.06 Million USD | -219.42% |
| 2022 FY | -5.88 Million USD | -70.69% |
| 2022 Q1 | -904 Thousand USD | 67.87% |
| 2022 Q3 | -958 Thousand USD | 0.62% |
| 2021 Q2 | 169 Thousand USD | 43.22% |
| 2021 FY | -3.44 Million USD | 48.3% |
| 2021 Q1 | 118 Thousand USD | 104.28% |
| 2021 Q4 | -2.81 Million USD | -1939.13% |
| 2021 Q3 | -138 Thousand USD | -181.66% |
| 2020 Q2 | -1.2 Million USD | 30.52% |
| 2020 FY | -6.67 Million USD | 40.74% |
| 2020 Q3 | -982 Thousand USD | 18.3% |
| 2020 Q4 | -2.75 Million USD | -180.75% |
| 2020 Q1 | -1.73 Million USD | 36.02% |
| 2019 Q2 | -2.65 Million USD | 25.34% |
| 2019 Q3 | -2.35 Million USD | 11.39% |
| 2019 Q1 | -3.55 Million USD | 25.21% |
| 2019 Q4 | -2.7 Million USD | -15.06% |
| 2019 FY | -11.25 Million USD | 20.66% |
| 2018 Q3 | -3.2 Million USD | -12.01% |
| 2018 FY | -14.18 Million USD | -9.36% |
| 2018 Q4 | -4.74 Million USD | -48.41% |
| 2018 Q2 | -2.85 Million USD | 15.55% |
| 2018 Q1 | -3.38 Million USD | -16.17% |
| 2017 Q3 | -3.56 Million USD | -83.76% |
| 2017 Q4 | -2.91 Million USD | 18.32% |
| 2017 Q1 | -2.57 Million USD | 10.07% |
| 2017 FY | -12.97 Million USD | -27.8% |
| 2017 Q2 | -1.94 Million USD | 24.54% |
| 2016 Q3 | -3.12 Million USD | -68.14% |
| 2016 FY | -10.15 Million USD | -52.46% |
| 2016 Q2 | -1.85 Million USD | 19.6% |
| 2016 Q1 | -2.31 Million USD | -39.89% |
| 2016 Q4 | -2.85 Million USD | 8.48% |
| 2015 Q4 | -1.65 Million USD | 15.24% |
| 2015 Q3 | -1.94 Million USD | -26.23% |
| 2015 Q2 | -1.54 Million USD | -1.98% |
| 2015 Q1 | -1.51 Million USD | 28.18% |
| 2015 FY | -6.65 Million USD | -10.05% |
| 2014 Q3 | -1.54 Million USD | -21.64% |
| 2014 Q4 | -2.1 Million USD | -36.35% |
| 2014 FY | -6.05 Million USD | -79.34% |
| 2014 Q2 | -1.27 Million USD | -12.88% |
| 2014 Q1 | -1.12 Million USD | 18.52% |
| 2013 Q2 | -817 Thousand USD | -65.05% |
| 2013 FY | -3.37 Million USD | 47.83% |
| 2013 Q3 | -680 Thousand USD | 16.77% |
| 2013 Q1 | -495 Thousand USD | 66.21% |
| 2013 Q4 | -1.38 Million USD | -103.24% |
| 2012 Q1 | -2.01 Million USD | -45.6% |
| 2012 Q3 | -2.35 Million USD | -273.65% |
| 2012 FY | -6.46 Million USD | 13.83% |
| 2012 Q4 | -1.46 Million USD | 37.77% |
| 2012 Q2 | -630 Thousand USD | 68.78% |
| 2011 Q2 | -1.64 Million USD | 31.34% |
| 2011 Q3 | -2.07 Million USD | -26.32% |
| 2011 Q4 | -1.38 Million USD | 33.3% |
| 2011 FY | -7.5 Million USD | 6.37% |
| 2011 Q1 | -2.39 Million USD | -64.67% |
| 2010 Q3 | -2 Million USD | 11.09% |
| 2010 Q2 | -2.25 Million USD | 2.0% |
| 2010 FY | -8.01 Million USD | 53.68% |
| 2010 Q1 | -2.3 Million USD | -2.36% |
| 2010 Q4 | -1.45 Million USD | 27.43% |
| 2009 Q4 | -2.24 Million USD | 28.41% |
| 2009 Q3 | -3.14 Million USD | 52.63% |
| 2009 Q2 | -6.62 Million USD | -30.63% |
| 2009 Q1 | -5.07 Million USD | 12.15% |
| 2009 FY | -17.3 Million USD | 22.82% |
| 2008 FY | -22.42 Million USD | -15.09% |
| 2008 Q2 | -5.67 Million USD | -4.86% |
| 2008 Q1 | -5.41 Million USD | 6.14% |
| 2008 Q3 | -5.55 Million USD | 2.2% |
| 2008 Q4 | -5.77 Million USD | -4.0% |
| 2007 Q3 | -5.11 Million USD | -19.06% |
| 2007 Q1 | 1.16 Million USD | 105.14% |
| 2007 Q4 | -5.77 Million USD | -12.76% |
| 2007 FY | -19.48 Million USD | 6.56% |
| 2007 Q2 | -4.29 Million USD | -468.93% |
| 2006 Q2 | 541 Thousand USD | 0.0% |
| 2006 Q3 | 751 Thousand USD | 38.82% |
| 2006 Q4 | -22.68 Million USD | -3120.51% |
| 2006 FY | -20.85 Million USD | -27.83% |
| 2006 Q1 | 541 Thousand USD | 103.12% |
| 2005 Q2 | 339 Thousand USD | 0.0% |
| 2005 Q3 | 339 Thousand USD | 0.0% |
| 2005 FY | -16.31 Million USD | -1908.43% |
| 2005 Q1 | 339 Thousand USD | 0.0% |
| 2005 Q4 | -17.32 Million USD | -5211.8% |
| 2004 FY | 902 Thousand USD | 161.44% |
| 2003 FY | -1.46 Million USD | -898.64% |
| 2002 FY | -147 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 102.816% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -86.902% |
| Embecta Corp. | 221.5 Million USD | 102.122% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 105.362% |
| PainReform Ltd. | -9.58 Million USD | 50.949% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 1.762% |
| SCYNEXIS, Inc. | 72.66 Million USD | 106.469% |
| Journey Medical Corporation | -2.07 Million USD | -126.773% |
| Safety Shot Inc | -12.18 Million USD | 61.417% |
| Alpha Teknova, Inc. | -35.56 Million USD | 86.781% |
| Bright Green Corporation | -8.89 Million USD | 47.129% |
| Procaps Group, S.A. | 38.97 Million USD | 112.062% |
| Alvotech | -354.86 Million USD | 98.675% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 110.008% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 68.872% |
| Cosmos Health Inc. | -21.83 Million USD | 78.467% |
| Dynavax Technologies Corporation | -37.02 Million USD | 87.304% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 96.978% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 97.05% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 1.762% |
| Theratechnologies Inc. | -10.62 Million USD | 55.764% |
| Harrow Health, Inc. | 580 Thousand USD | 910.517% |
| Biofrontera Inc. | -22.67 Million USD | 79.27% |
| DURECT Corporation | -36.88 Million USD | 87.255% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 10.78% |
| Cronos Group Inc. | -81.37 Million USD | 94.223% |
| OptiNose, Inc. | -22.74 Million USD | 79.334% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 102.249% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 87.993% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 137.215% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 137.533% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -8.41% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 24.309% |
| Radius Health, Inc. | -3.92 Million USD | -19.771% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -33.295% |
| ProPhase Labs, Inc. | -21.61 Million USD | 78.249% |
| Phibro Animal Health Corporation | 53.31 Million USD | 108.817% |
| Procaps Group S.A. | 52.32 Million USD | 108.984% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 44.843% |
| Viatris Inc. | 766.2 Million USD | 100.614% |
| Rockwell Medical, Inc. | -6.67 Million USD | 29.52% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 10.525% |
| SIGA Technologies, Inc. | 83.62 Million USD | 105.622% |
| Tilray Brands, Inc. | -174.74 Million USD | 97.31% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 150.38% |
| Shineco, Inc. | -17.06 Million USD | 72.454% |
| PetIQ, Inc. | 60.01 Million USD | 107.833% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 0.754% |
| Incannex Healthcare Limited | -30.04 Million USD | 84.351% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 101.874% |
| Alimera Sciences, Inc. | -1.47 Million USD | -219.579% |
| Silver Spike Investment Corp. | 7.34 Million USD | 164.045% |
| Assertio Holdings, Inc. | -243.53 Million USD | 98.07% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 20.219% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 65.478% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 69.854% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 76.554% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 96.59% |
| Hempacco Co., Inc. | -8.81 Million USD | 46.654% |
| Talphera, Inc. | -16.88 Million USD | 72.165% |
| Alvotech | -354.86 Million USD | 98.675% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 108.794% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 101.289% |
| Currenc Group, Inc. | -6.64 Million USD | 29.263% |
| Kamada Ltd. | 10.06 Million USD | 146.711% |
| Indivior PLC | -4 Million USD | -17.525% |
| Evoke Pharma, Inc. | -7.43 Million USD | 36.737% |
| Flora Growth Corp. | -50.35 Million USD | 90.664% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 76.554% |
| Evolus, Inc. | -49.23 Million USD | 90.452% |
| HUTCHMED (China) Limited | 18.37 Million USD | 125.584% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 102.386% |
| Akanda Corp. | -10.05 Million USD | 53.23% |